AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06575179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine high-dose
Description: The high-dose dexmedetomidine group received a 150 μg/h loading dose over 15 minutes, followed by 120 μg/h maintenance infusion intravenously.
Study NCT06243952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARC-BSI Lumbar system
Description: Implantation of a 64 channel - ECoG array over the sensory motor cortex of the lower limbs, combined with an implantation of 16 channel spinal cord stimulation system over the lumbar region. The decoded motor intentions are driving the implanted spinal cord stimulation system. Brain-controlled spinal cord stimulation is used for training and rehabilitation to recover voluntary movements.
Study NCT05200013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAT7104
Description: Symmetric IgG-like AntiPD-L1/CD47 Bispecific Antibody Solution for Injection BAT7104 injection available in 100 mg/2 mL (50 mg/mL) dosage
Study NCT06649513 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: eye drops (Tropicamid)
Description: Mydriatic + cycloplegic eye drops are given to measure refractive error and to image the full retina.
Study NCT06221488 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TB infection testing
Description: Diagnostic testing with existing and novel tests to evaluate for TB infection and disease
Study NCT05122910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management and Resilience Training - Moral Resilience (SMART-MR) program
Description: All participants will attend an initial 2.5 hour workshop and a 1-hour follow-up workshop. The workshop will include general resilience strategies with a focus on the moral/ethical dimensions of clinical practice to offer participants specific skills to address ethical challenges. In addition to the workshops, there will be follow-up supplemental resources.
Study NCT05077176 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac
Description: One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
Study NCT05077176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Turkovac
Description: One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
Study NCT05470621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PlayOn! playground curriculum
Description: A staff and student training to implement a playground curriculum in after-school and recess settings
Study NCT06124482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Knee arthroplasty
Description: The FHK-CK prosthesis (non CE-Marked, class III) is to be implanted with the use of FHK-CK instruments. The surgery has to be performed in accordance with the practice/guidelines, FHK-CK Instruction For Use (IFU) and surgical techniques documents.
Study NCT04759742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: According to previous clinical experience, 0.5% ropivacaine was given in the subarachnoid cavity, and the initial dose was set at 2.5 mL (12.5mg). Dixon's up-and down method was adopted to adjust or down-adjust the dose of ropivacaine in the next patient according to the experimental results of the previous patient, and the adjusted dose was 0.1 mL (0.5mg).
Study NCT01003704 — intervention group
Intervention type: PROCEDURE
Intervention: Lower extremity amputation
Study NCT04736017 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TSB Axo
Description: The TSB Axo is a wearable biosignal recording device combined with an auditory stimulation. The device consists of pre-gelled biosignal electrodes, headphones integrated in a headband, and a biosignal processing module.
Study NCT04736017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TSB Axo
Description: The TSB Axo is a wearable biosignal recording device combined with an auditory stimulation. The device consists of pre-gelled biosignal electrodes, headphones integrated in a headband, and a biosignal processing module.
Study NCT06149052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMART TRAINING
Description: Patients in Group A received SMART training intervention. For sensory stimulation planter massage was given, and it was applied to entire planter surface. Grade III anterior to posterior talocrural joint mobilization was given (26). For balance, single and double leg stance was performed. For functional training, lateral hops and SEBT was performed. And at the end, for resistance training, theraband was used with normal ankle joint movement. There is a progress in focus between the five domains over the 3weeks, as described below: The domains S and M are present across the whole intervention. In week 1, the main focus is on the A domain, in week 2 on the R domain, and in week 3 on the T domain. During the 3-week intervention period, 3 training sessions was held per week each lasting approximately 45 - 60 min, including 10 min warm up
Study NCT06149052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIRE training
Description: Patients in Group B was received foot intensive rehabilitation (FIRE).The FIRE intervention was include the progressive balance training, ankle and hip strengthening, range of motion exercises and foot massage. Plantar massage consisted of two, 1-min plantar massages with a 1-min rest between sets. Four previously established exercises were targeted the IFMs including the short-foot, toe-spread-out, hallux extension, and lesser-toe extension
Study NCT06450574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine (Xeloda)
Description: Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy
Study NCT06450574 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 50.4 Gy
Description: Radiotherapy was administered in daily fractions of 1.8 Gy 5 days a week according to standard schema. The total dose is 45 Gy plus a boost of 5.4 Gy to the tumor area
Study NCT06450574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal Endoscopic Microsurgery (TEM)
Description: 10 weeks after Chemoradiotherapy
Study NCT06450574 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transanal Endoscopic Microsurgery
Description: Standard surgical treatment of T1, N0, M0 rectal cancer. Early after diagnosis
Study NCT04932382 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Misoprostol
Description: will be used 3 h before IUD insertion
Study NCT04932382 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: IUD
Description: a copper T380A IUD
Study NCT05670236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: 10 mL of 1% lidocaine hydrochloride for each intraarticular knee injection
Study NCT05666544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based patient decision aid
Description: After the clinic, use web-based patient decision aid of renal replacement therapy to conduct education.
Study NCT05666544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written health education leaflets
Description: After the clinic, use a written health education leaflet on renal replacement therapy to conduct education.
Study NCT05445856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone is administered as a single intravenous dose after induction of anesthesia and prior to initiation of surgery
Study NCT05445856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl is administered as a single intravenous dose after induction of anesthesia and prior to initiation of surgery
Study NCT06184490 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone position with thoraco-abdominal cushion
Description: Prone position with cushions positioned laterally on the chest, abdomen, and pelvis
Study NCT05001295 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Physical Activity
Description: Following the guidelines of NICE, the program to be followed by the IG is designed so that the intervention lasts 5 weeks, divided into 4 levels of progressive intensity, in which sessions of 30 to 45 minutes of aerobic exercise will be carried out 2 days a week. week.
Study NCT05001295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Following the guidelines of NICE, the program to be followed by the IG is designed so that the intervention lasts 5 weeks, divided into 4 levels of progressive intensity, in which sessions of 30 to 45 minutes of aerobic exercise will be carried out 2 days a week. week.
Study NCT04988971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a compound glutamine capsule
Description: A compound glutamine capsule was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
Study NCT04765813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment to quit smoking along with an App with active therapeutic components
Description: Cognitive-behavioral smoking cessation treatment components will be: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem-solving training, change tobacco-related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Participants will use a smartphone App with therapeutic components during the intervention (8 weeks) and follow-up period (time frame: one year).
Study NCT04765813 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral treatment to quit smoking along with a control App
Description: Cognitive-behavioral smoking cessation treatment components will be: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem-solving training, change tobacco-related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Participants will use a control smartphone App (only to access session materials) during the intervention period (8 weeks).
Study NCT06353919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Nidra
Description: Recordings were created to allow participants access to a variety of Yoga Nidra practices. Participants will be instructed to complete a 30-minute Yoga Nidra 3-5 times per week, at any time of day or night (including before bed and/or during bouts of sleeplessness). This duration and frequency is informed by previous studies.~Related to intentionally decreasing BZRA use, the recording requests each practitioner to set a resolve/personal goal at the start of each practice, and they are asked to repeat it again at the end. In our study, participants will be asked to develop a short and simple resolve in their own words, related to reducing BZRA use, improving sleep and decreasing anxiety, and they will be asked to recite it at each practice.
Study NCT06353919 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene, Anxiety, and Benzodiazepine Receptor Agonist Education
Description: Participants will be instructed to access excerpts from standardized and trusted materials through our online platform for 30 minutes, 3-5 times per week.
Study NCT04988971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: a compound glutamine capsule simulated placebo
Description: a compound glutamine capsule simulated placebo was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
Study NCT06108089 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]MISO-PET/CT
Description: 18F\]MISO-PET/CT will be acquired in each patient as the standard of references of tumor hypoxia.
Study NCT05978713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT06523023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An integrated online program
Description: Our integrated online program combines validated psychoeducational materials on dissociation with components of strucutred writing therapy.
Study NCT05619913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin mesilate is a first-in-class halichondrin B-based, microtubule dynamics inhibitor7. It inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into non-productive aggregates.
Study NCT05619913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
Study NCT06523023 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: An integrated online program
Description: Our integrated online program combines validated psychoeducational materials on dissociation with components of strucutred writing therapy.
Study NCT05404880 — intervention group
Intervention type: DEVICE
Intervention: EDWARDS INSPIRIS RESILIA Aortic Valve
Description: Surgical replacement of the aortic valve with the INSPIRIS RESILIA Aortic Valve.
Study NCT04842617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 combined with endocrine therapy
Study NCT04842617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo combined with endocrine therapy
Study NCT05774795 — intervention group
Intervention type: PROCEDURE
Intervention: Mitral valve surgery
Description: Mitral valve repair or replacement to treat mitral regurgitation
Study NCT05774795 — intervention group
Intervention type: PROCEDURE
Intervention: Aortic valve surgery
Description: Aortic valve replacement to treat aortic regurgitation
Study NCT05808530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy
Description: CST involves the use of standard tasks that focus on cognitive functions, designed to meet varying levels of difficulty in accordance with the individual's ability and rehabilitation. A detailed guide for CST is available for a range of health and care professionals, including care workers, occupational therapists, psychologists, and nurses (https://www.ucl.ac.uk/international-cognitive-stimulation-therapy/) publications/cst-manuals). The CST application consists of 14 sessions of 45-50 minutes, 2 days a week.~Intervention Group Week 1=Getting acquainted and applying pre-tests Week 2=Physical games and Sounds Week 3=Childhood and Food Week 4=Current events and Faces / Scenes Week 5=Word association and Creativity Week 6=Categorizing Objects and Orientation Week 7= Money usage and Games Week 8=Word Games and Team Competition Week 9=Closing and post-test application
Study NCT05209126 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: Acute effects of beetroot juice ingestion on neuromuscular performance in female rugby players
Study NCT05209126 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot juice
Description: Acute effects of beetroot juice ingestion on neuromuscular performance in female rugby players
Study NCT05099614 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride injection solution, SmartDose wearable auto injector and mobile respiratory sensing system
Description: 1.2 mg of naloxone hydrochloride is administered to healthy adults using the SmartDose wearable auto injector and the mobile respiratory sensing system.
Study NCT05023941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Start orally take acetazolamide 125mg twice daily, 2 days before entering the hypoxic chamber. Subjects will enter the hypoxic room at 9am on the third day. At that time, the subject should have taken the drug 5 times.
Study NCT05023941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Start orally take acetazolamide 125mg twice daily, 2 days before entering the hypoxic chamber. Subjects will enter the hypoxic room at 9am on the third day. At that time, the subject should have taken the drug 5 times.
Study NCT05023941 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Doctormate® (twice daily for 6 days)
Description: Start RIPC training twice daily, 6 days before entering the hypoxic chamber. RIPC will be induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®). Each training will be comprised of 5 cycles of bilateral upper limb ischemia and reperfusion, which will be induced by 2 cuffs placed around the upper arms respectively and inflated to 200mmHg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. Subjects will enter the hypoxic room at 9am on the seventh day. At that time, the subject should have finished 13 times of RIPC training.
Study NCT05023941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doctormate® (forth daily for 3 days)
Description: Start RIPC training forth daily, 3 days before entering the hypoxic chamber. RIPC will be induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®). Each training will be comprised of 5 cycles of bilateral upper limb ischemia and reperfusion, which will be induced by 2 cuffs placed around the upper arms respectively and inflated to 200mmHg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. Subjects will enter the hypoxic room at 9am on the forth day. At that time, the subject should have finished 13 times of RIPC training.
Study NCT01561092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 5 or 10 mg escitalopram tablets administered orally once daily
Study NCT01561092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets
Study NCT06172218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flo
Description: sterile, micronized human amniotic membrane product derived from placenta and umbilical cord
Study NCT06172218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: sterile, preservative free 0.9% NaCl
Study NCT06172218 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: sterile, preservative free 0.9% NaCl
Study NCT05170308 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CO2 fractional laser
Description: The study subjects' body will be divided into two equal halves along sagittal midline section with one side receiving treatment with fractional CO2 laser (experimental) to treat dyspigmentation in lichen planus pigmentosus
Study NCT05400070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy 1
Description: Dosing regimen Sintilimab (200mg fixed dose) iv, d1, q3w + anlotinib 10mg, po, qd1-14, q3w, was evaluated after 3 cycles of chemotherapy and stopped for 3 weeks (21 days) after surgery for 4-6 weeks (21-42 days) after the last dose.
Study NCT04582916 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 11C-MCI
Description: Injected IV followed by PET scanning
Study NCT04582916 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 11CPS13
Description: Injected IV followed by PET scanning
Study NCT06605222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-7787 injection
Description: Firstly Dose Escalation and Dose Expansion of SHR-7787 injection monotherapy should be conducted.
Study NCT06666751 — intervention group
Intervention type: PROCEDURE
Intervention: Cataract plus Microstent surgery
Description: Both the Hydrus microstent and iStent Inject W are used in combination with cataract surgery, in order to help lower intraocular pressure for patients with open-angle glaucoma. The microstent is a small flexible device that is inserted into the eye during cataract surgery in order to improve the outflow of fluid from the eye.
Study NCT06668610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StarStim 32, Neuroelectrics, Spain - Real multifocal tDCS
Description: Real multifocal tDCS will be delivered with an intensity of 2.0 mA over 8 electrodes positioned over the frontal and temporal areas in the left hemisphere according to the international 10/10 EEG system. The overall duration of stimulation will be set at 20 minutes.
Study NCT06668610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StarStim 32, Neuroelectrics, Spain - Sham multifocal tDCS
Description: Sham multifocal tDCS will be delivered with an intensity of 2.0 mA over 8 electrodes positioned over the frontal and temporal areas in the left hemisphere according to the international 10/10 EEG system. The overall duration of stimulation will be set at 30 seconds.
Study NCT06668610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive treatment
Description: During the two cycles, all participants will undergo traditional cognitive stimulation therapy, involving paper-and-pencil exercise and computerised activity on several cognitive domains including memory, attention, and executive functions (duration 30-40 minutes) .